CHO-K1

CHO-K1 chinese hamster ovary

Cell Type:
Ovary Epith.
Tissue Origin:
ovarian
Species:
hamster
Research Area:
Cancer Research/Cell Biology
Gene Expression
Cell Characteristics:
Adherent

Recommended Media

ProCHO™ Protein-free CHO Media were developed specifically to facilitate the production and downstream processing of recombinant proteins expressed in CHO cells. These protein-free formulations support high-density cultures without the need for animal derived components.
Very low levels of recombinant insulin facilitate both downstream purification and regulatory compliance.

The following media systems are available:
- ProCHO™ 4 Medium – For concurrent transition of adherent CHO cells to serum-free and suspension culture; supports faster doubling times
- ProCHO™ 5 Medium – For CHO cells already growing in suspension; supports increased protein production

Storage = 2°C to 8°C

12-029Q - ProCHO™ 4 with phenol red and 0.1% Pluronic® F-68; but without L-glutamine, hypoxanthine, or thymidine.
04-919Q - ProCHO™ 4 with 0.1% Pluronic® F-68; and without phenol red, L-glutamine, hypoxanthine, or thymidine.

12-766Q - ProCHO™ 5  with 0.1% Pluronic® F-68; and without L-glutamine, phenol red, hypoxanthine, or thymidine.
BE15-766 - ProCHO™ 5 powder without phenol red

PowerCHO™ Chemically Defined, Serum-free and hydrolysate-free CHO Media are non-animal origin media designed to support the growth of CHO cell lines, particularly high-density suspension cultures.

For therapeutic bioprocessing applications, these protein-free formulations also facilitate both downstream purification and regulatory compliance.

Storage = 2°C to 8°C

12-771Q - PowerCHO™-2 (with HEPES and Pluronic® F-68, without phenol red, hypoxanthine, thymidine, or L-glutamine)
BE15-771N - PowerCHO™-2 Powder Kit (with HEPES and Pluronic® F-68, without phenol red, hypoxanthine, thymidine, or L-glutamine)

discontinued:

12-770Q - PowerCHO™-1 (with HEPES and Pluronic® F-68, without phenol red, hypoxanthine, thymidine, or L-glutamine)
12-772Q - PowerCHO™-3 (with HEPES and Pluronic® F-68, without phenol red, hypoxanthine, thymidine, or L-glutamine)

ProFreeze™-CDM, NAO, Chemically Defined Freeze Medium (2X) is universally suitable for cryopreserving many cell types in the absence of fetal bovine serum (FBS), which is particularly advantageous for freezing of cells cultured in a serum-free and animal component-free environment.
This protein-free freezing medium contains no animal derived components, insulin, or hydrolysate, and maintains high cell viability upon recovery from frozen storage.

ProFreeze™ Medium requires the addition of 15% reagent or spectrophotometric grade dimethylsulfoxide (DMSO) at time of use.

Storage = 2°C to 8°C

eCHO™ Basal Medium and Feed is a chemically defined, hydrolysate-free, serum-free, and non-animal origin medium for supporting high-density CHO cells in suspension.

Improved cell growth and protein yield are achieved when adding the eCHO™ Feed. The eCHO™ Medium is compatible with batch and fed-batch culture.
eCHO™ Medium is available in powder and liquid formats. The powder consists of only one component for the eCHO™ Basal Medium and one for the eCHO™ Feed for minimal preparation time. 

BEBP12-933Q    eCHO™ Basal Medium, Liquid, 1 L
BE15-933D         eCHO™ Basal Medium, Powder, 10 L
BE15-933F         eCHO™ Basal Medium, Powder, 50 L
BE15-932D         eCHO™ Feed, Powder, 10 L
BE15-932F         eCHO™ Feed, Powder, 50 L

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
Filter:
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
T

U-023

1e6 84% ±4 96% ±1 Plasmid (general) 2 µg 100 µl I/II/2b
T U-023 1e6 94% ±2 87% Plasmid (general) 2 µg 100 µl I/II/2b
SF

DT-133

2e5 80-84% 68-74% Plasmid (general) 0.2 µg 20 µl 4D X-Unit
SF

DT-133

1e6 71-79% 62-72% Plasmid (general) 1 µg 100 µl 4D X-Unit
T

U-027

1e6 84% ±2 53% ±14 Plasmid (general) 5 µg 100 µl I/II/2b
SF 96-DT-133 2e5 86% ±6 97% ±1 Plasmid (general) 0.4 µg 20 µl 96-well

Citations (13)

Categories:
Transfection, Cell Lines and Primary Cancer Cells 
Authors:
Lang S1, Drewello D1, Wichter J2, Nommay A1, Wilms B1, Knopf HP1, Jostock T3. 
In:
Biotechnol Bioeng (2016) 113: 11 
Categories:
Live Cell Imaging 
Authors:
Brunetti J, Depau L, Falciani C, Gentile M, Mandarini E, Riolo G, Lupetti P, Pini A, Bracci L 
In:
Scientific Reports (2016) 6: 27174 
Categories:
Transfection 
Authors:
Kah Fai Chan, Wahyu Shahreel, Corrine Wan, Gavin Teo, Noor Hayati, Shi Jie Tay, Wen Han Tong, Yuansheng Yang, Pauline M. Rudd, Peiqing Zhang, Zhiwei Song 
In:
Biotechnology Journal (2015) -: - 
Categories:
Classical Media and Reagents, Serum-free and Speciality Media, Transfection 
Authors:
Maria Cherian R1, Gaunitz S, Nilsson A, Liu J, Karlsson NG, Holgersson J. 
In:
Glycobiology (2014) 24 (1): 26-38 
Categories:
Classical Media and Reagents, Serum-free and Speciality Media, Transfection 
Authors:
Ilyushin DG1, Smirnov IV, Belogurov AA Jr, Dyachenko IA, Zharmukhamedova TIu, Novozhilova TI, Bychikhin EA, Serebryakova MV, Kharybin ON, Murashev AN, Anikienko KA, Nikolaev EN, Ponomarenko NA, Genkin DD, Blackburn GM, Masson P, Gabibov AG 
In:
Proc Natl Acad Sci USA (2013) 110(4): 1243–1248 
Categories:
Transfection 
Authors:
Brown JM, Chung S, Das A, Shelness G, Rudel LL, Yu L 
In:
J Lipid Res (2007) 48(10): 2295-305 
Categories:
Transfection 
Authors:
Haschemi A, Wagner O, Marculescu R, Wegiel B, Robson SC, Gagliani N, Gallo D, Chen JF, Bach FH, Otterbein LE 
In:
J Immunol (2007) 178(9): 5921-9 
Categories:
Transfection 
Authors:
Nissom PM, Lo SL, Lo JC, Ong PF, Lim JW, Ou K, Liang RC, Seow TK, Chung MC 
In:
FEBS Lett (2006) 580(9): 2216-26 
Categories:
Transfection 
Authors:
Thompson J and Begenisich T 
In:
J Gen Physiol (2006) 127(2): 159-169 
Categories:
Transfection 
Authors:
Rosenblum MD, Woodliff JE, Madsen NA, McOlash LJ, Keller MR and Truitt RL 
In:
J Invest Dermatol (2005) 125(6): 1130-1138 
Categories:
Transfection 
Authors:
Gresch O, Engel FB, Nesic D, Tran TT, England HM, Hickman ES, Korner I, Gan L, Chen S, Castro-Obregon S, Hammermann R, Wolf J, Muller-Hartmann H, Nix M, Siebenkotten G, Kraus G and Lun K 
In:
Methods (2004) 33(2): 151-163 
Categories:
Transfection 
Authors:
Zhang J, Dudley-Rucker N, Crowley JR, Lopez-Perez E, Issandou M, Schaffer JE and Ory DS 
In:
J Lipid Res (2004) 45(2): 223-231 
Categories:
Transfection 
Authors:
Bartholome B, Spies CM, Gaber T, Schuchmann S, Berki T, Kunkel D, Bienert M, Radbruch A, Burmester G-R, Lauster R, Scheffold A and Buttgereit F 
In:
FASEB J (2004) 18(1): 70-80 
+ Show All